Known targets — ChEMBL curated mechanism
CDK2CDK4CDK6CHEK1PDPK1PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3
The experimentally established mechanism targets of Ucn-01. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ known ✓ | Q04759 | 14/20 | 1.00 |
| ▸ | PRKCD known ✓ | Q05655 | 13/20 | 1.00 |
| ▸ | PRKD3 known ✓ | O94806 | 12/20 | 1.00 |
| ▸ | PRKCG known ✓ | P05129 | 12/20 | 1.00 |
| ▸ | PRKCZ known ✓ | Q05513 | 12/20 | 1.00 |
| ▸ | PRKCE known ✓ | Q02156 | 12/20 | 1.00 |
| ▸ | PRKCB known ✓ | P05771 | 11/20 | 1.00 |
| ▸ | PRKCA known ✓ | P17252 | 11/20 | 1.00 |
| ▸ | PRKCH known ✓ | P24723 | 11/20 | 1.00 |
| ▸ | PRKCI known ✓ | P41743 | 11/20 | 1.00 |
| ▸ | PRKD1 known ✓ | Q15139 | 11/20 | 1.00 |
| ▸ | CHEK1 known ✓ | O14757 | 5/20 | 1.00 |
| ▸ | CDK2 known ✓ | P24941 | 3/20 | 1.00 |
| ▸ | PDPK1 known ✓ | O15530 | 3/20 | 0.73 |
| ▸ | CDK4 known ✓ | P11802 | 2/20 | 0.73 |
| ▸ | CDK6 known ✓ | Q00534 | 1/20 | 0.73 |
| ▸ | PRKACA | P17612 | 9/20 | 1.00 |
| ▸ | PRKACG | P22612 | 8/20 | 1.00 |
| ▸ | PRKACB | P22694 | 8/20 | 1.00 |
| ▸ | EGFR | P00533 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ucn-01 SCHEMBL29354706 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL14217901 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL13169435 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL13170168 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL20068300 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL17470230 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL24105650 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL14190736 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL13933132 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL1551632 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2012 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174659-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2024-05-30 | — | — | US | claimed |
| US-20240132521-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. | 2024-04-25 | — | — | US | claimed |
| EP-4295912-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Daiichi Sankyo, Inc. (US) | 2023-12-27 | — | — | EP | claimed |
| WO-2023147063-A2 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2023-08-03 | — | — | WO | claimed |
| US-20230081426-A1 | COMPOUNDS AND METHODS FOR KRAS MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2023-03-16 | — | — | US | claimed |
| WO-2023034381-A1 | QUANTITATIVE SYSTEMS PHARMACOLOGY METHODS FOR IDENTIFYING THERAPEUTICS FOR DISEASE STATES | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-03-09 | — | — | WO | claimed |
| EP-4139296-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Immuno Oncology, SA (CH) | 2023-03-01 | — | — | EP | claimed |
| US-11446287-B2 | Compounds and methods for EP300 or CBP modulation and indications therefor | OPNA IMMUNO-ONCOLOGY SA (CH) | 2022-09-20 | — | — | US | claimed |
| US-11382903-B2 | Cancer therapy | ASLAN PHARMACEUTICALS PTE. LTD. (SG) | 2022-07-12 | — | — | US | claimed |
| US-20220144805-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2022-05-12 | — | — | US | claimed |
| WO-2004038020-A1 | TARGET GENES FOR THE DIAGNOSIS AND TREATMENT OF CANCER | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2004-05-06 | — | — | WO | claimed |
| EP-1369482-A1 | Target genes for the diagnosis and treatment of cancer | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2003-12-10 | — | — | EP | claimed |
| WO-2003086470-A2 | SMAC-PEPTIDES AS THERAPEUTICS AGAINST CANCER AND AUTOIMMUNE DISEASES | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2003-10-23 | — | — | WO | claimed |
| WO-2003068929-A9 | METHODS OF INHIBITING HIV-1 VPR ACTIVITY AND HIV-1 INFECTIVITY USING ATR OR RAD17 INHIBITORS | UNIV ROCHESTER (US) | 2003-10-23 | — | — | WO | claimed |
| EP-1354953-A1 | Smac-peptides as therapeutics against cancer and autoimmune diseases | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2003-10-22 | — | — | EP | claimed |
| EP-1354952-A1 | Smac-peptides as therapeutics against cancer and autoimmune diseases | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2003-10-22 | — | — | EP | claimed |
| WO-2003068929-A2 | METHODS OF INHIBITING HIV-1 VPR ACTIVITY AND HIV-1 INFECTIVITY USING ATR OR RAD17 INHIBITORS | UNIVERSITY OF ROCHESTER (US) | 2003-08-21 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2003037323-A2 | INHIBITORS OF THE FATTY ACID OXIDATION FOR PROPHYLAXIS AND TREATMENT OF DISEASES RELATED TO MITOCHONDRIAL DYSFUNCTION | MEDIGENE AG Gesellschaft für Molekularbiologische Kardiologie und Onkologie (DE) | 2003-05-08 | — | — | WO | claimed |
| US-6214821-B1 | TOPOISOMERASE INHIBITOR AND 7-HYDROXYSTAUROSPORINE | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION | 2001-04-10 | — | — | US | claimed |